Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of Response
Sponsor: Central Hospital, Nancy, France
Summary
177Lutetium-PSMA-617 is an established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Early response assessment is critical for optimizing patient management. Response Evaluation Criteria in Prostate Imaging (RECIP) 1.0, initially developed for Positon Emission Tomography (PET) with 68Ga-PSMA, have demonstrated prognostic value, particularly after two treatment cycles. Recent studies suggest that SPECT at cycle 2 provides prognostic information, although it reflects only the first treatment cycle, whereas PET-based RECIP, assessed after cycle 2, captures the effect of two cycles. This study aims to evaluate the prognostic value of quantitative 177Lu-PSMA-SPECT biomarkers and determine the optimal timing for RECIP-based assessment.
Official title: Prognostic Value of [¹⁷⁷Lu]Lu-PSMA SPECT and Timing of RECIP Assessment in mCRPC
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
280
Start Date
2026-07-01
Completion Date
2026-12-01
Last Updated
2026-06-12
Healthy Volunteers
Not specified